Iodinated contrast agent-induced nephropathy;Mit jodhaltigen kontrastmitteln induzierte nephropathie

Radiologe

Volumn 47, Issue 9, 2007, Pages 761-767

  Erley, C ^a  

^a ST JOSEPH KRANKENHAUS   (Germany)

Author keywords

Angiography; Chronic kidney disease; Computed tomography (CT); Contrast application; Contrast media; Contrast induced nephropathy

Indexed keywords

ACETYLCYSTEINE; ANTIHYPERTENSIVE AGENT; IODINATED CONTRAST MEDIUM; MANNITOL; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; THEOPHYLLINE;

ANGIOGRAPHY; CLINICAL TRIAL; DIALYSIS; DISEASE COURSE; HEMOFILTRATION; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; MORTALITY; PREVENTION AND CONTROL; PROPHYLAXIS; REVIEW; RISK FACTOR;

ACETYLCYSTEINE; AGE FACTORS; ANGIOGRAPHY; CLINICAL TRIALS AS TOPIC; CONTRAST MEDIA; DIABETES COMPLICATIONS; FREE RADICAL SCAVENGERS; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, ACUTE; RENAL REPLACEMENT THERAPY; RISK FACTORS; THEOPHYLLINE; TOMOGRAPHY, X-RAY COMPUTED; VASODILATOR AGENTS;

EID: 34648813886     PISSN: 0033832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00117-007-1549-x     Document Type: Review

References (68)

1. Nash K, Hafeez A, Hou S (2002) Hospital-acquired renal insufficiency. Am J Kidney Dis 39: 930-936
2. Bartholomew BA, Harjai KJ, Dukkipati S etb al. (2004) Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 93: 1515-1519
3. Mehran R, Aymong ED, Nikolsky E et al. (2004) A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 44: 1393-1399
4. McCarthy CS, Becker JA (1992) Multiple myeloma and contrast media. Radiology 183: 519-521
5. Berg KJ (2000) Nephrotoxicity related to contrast media. Scand J Urol Nephrol 34: 317-322
6. Madyoon H, Croushore L (2001) Use of fenoldopam for prevention of radiocontrast nephropathy in the cardiac catheterization laboratory: a case series. J Interv Cardiol 14: 179-185
7. McCullough PA, Wolyn R, Rocher LL et al. (1997) Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 103: 368-375
8. Manske CL, Sprafka JM, Strony JT, Wang Y (1990) Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography, Am J Med 89: 615-620
9. Marenzi G, Lauri G, Assanelli E et al. (2004) Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 44: 1780-1785
10. Gruberg L, Mintz GS, Mehran R et al. (2000) The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 36: 1542-1548
11. Rihal CS, Textor SC, Grill DE et al. (2002) Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105: 2259-2264
12. Levy EM, Viscoli CM, Horwitz RI (1996) The effect of acute renal failure on mortality: a cohort analysis. J A M A 275: 1489-1494
13. Solomon R, Deray G (2006) How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int [suppl]: S51-S53
14. Anto HR, Chou SY, Porush JG, Shapiro WB (1981) Infusion intravenous pyelography and renal function. Effect of hypertonic mannitol in patients with chronic renal insufficiency. Arch Intern Med 141: 1652-1656
15. Eisenberg RL, Bank WO, Hedgock MW (1981) Renal failure after major angiography can be avoided with hydration. Am J Radiol 136: 859-861
16. Kerstein MD, Puyau FA (1984) Value of periangiography hydration. Surgery 96: 919-922
17. Solomon R, Werner C, Mann D et al. (1994) Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331: 1416-1420
18. Mueller C, Buerkle G, Büttner HJ et al. (2002) Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 162: 32
19. Clavijo LC, Pinto TL, Kuchulakanti PK et al. (2006) Effect of a rapid intra-arterial infusion of dextrose 5% prior to coronary angiography on frequency of contrast-induced nephropathy in high-risk patients. Am J Cardiol 97: 981-983
20. Merten GJ, Burgess WP, Gray LV et al. (2004) Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 291: 2328-2334
21. Recio-Mayoral A, Chaparro M, Prado B et al. (2007) The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol 49: 1283-1288
22. Briguori C, Airoldi F, D'Andrea D et al. (2007) Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 115: 1211-1217
23. Taylor AJ, Hotchkiss D, Morse RW, McCabe J (1998) PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest 114: 1570-1574
24. Krasuski RA, Beard BM, Geoghagan JD et al. (2003) Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study. J Invasive Cardiol 15: 699-702
25. Trivedi HS, Moore H, Nasr S et al. (2003) A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 93: C29-C34
26. Bader BD, Berger ED, Heede MB et al. (2004) What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin Nephrol 62: 1-7
27. Dussol B, Morange S, Loundoun A et al. (2006) A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant 21: 2120-2126
28. Stone GW, McCullough PA, Tumlin JA et al. (2003) Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 290: 2284-2291
29. Kurnik BR, Allgren RL, Genter FC et al. (1998) Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 31: 674-680
30. Khoury Z, Schlicht JR, Como J et al. (1995) The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy 15: 59-65
31. Albert SG, Shapiro MJ, Brown WW et al. (1994) Analysis of radiocontrast-induced nephropathy by dual-labeled radionuclide clearance. Invest Radiol 29: 618-623
32. Miller HI, Dascalu A, Rassin TA et al. (2003) Effects of an acute dose of L-arginine during coronary angiography in patients with chronic renal failure: a randomized, parallel, double-blind clinical trial. Am J Nephrol 23: 91-95
33. Wang A, Holcslaw T, Bashore TM et al. (2000) Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 57: 1675-1680
34. Gupta RK, Kapoor A, Tewari S et al. (1999) Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomized study. Indian Heart J 51: 521-526
35. Toprak O, Cirit M, Bayata S et al. (2003) [The effect of pre-procedural captopril on contrast-induced nephropathy in patients who underwent coronary angiography]. Anadolu Kardiyol Derg 3: 98-103
36. Gurkowski L, MacDougall M, Wiegmann T (1995) Effects of misoprostol on contrast-induced renal dysfunction. Am J Ther 2: 837-842
37. Koch JA, Plum J, Grabensee B et al. (2000) Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? Nephrol Dial Transplant 15: 43-49
38. Spargias K, Adreanides E, Giamouzis G et al. (2006) Iloprost for prevention of contrast-mediated nephropathy in high-risk patients undergoing a coronary procedure. Results of a randomized pilot study. Eur J Clin Pharmacol 62: 589-595
39. Tepel M, van der Giet M, Schwarzfeld C et al. (2000) Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343: 180-184
40. Pannu N, Wiebe N, Tonelli M (2006) Prophylaxis strategies for contrast-induced nephropathy. JAMA 295: 2765-2779
41. Bagshaw SM, McAlister FA, Manns BJ, Ghali WA (2006) Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. Arch Intern Med 166: 161-166
42. Marenzi G, Assanelli E, Marana I et al. (2006) N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 354: 2773-2782
43. Miner SE, Dzavik V, Nguyen-Ho P et al. (2004) N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J 148: 690-695
44. Hoffmann U, Fischereder M, Kruger B et al. (2004) The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 15: 407-410
45. Erley CM, Heyne N, Burgert K et al. (1997) Prevention of radiocontrast induced nephropathy by adenosine antagonists in rats with chronic nitric oxide deficiency. J Am Soc Nephrol 8: 1125-1132
46. Erley CM, Duda SH, Rehfuss D et al. (1999) Prevention of radiocontrast-media-induced nephropathy in patients with preexisting renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant 14: 1146-1149
47. Erley CM, Duda SH, Schlepckow S et al. (1994) Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 45: 1425-1431
48. Ix JH, McCulloch CE, Chertow GM (2004) Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant 19: 2747-2753
49. Huber W, Eckel F, Hennig M et al. (2006) Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study. Radiology 239: 793-804
50. Dzgoeva FU, Milovanov I, Kutyrina IM (1995) [Acute kidney failure related to the use of x-ray contrast agents and indomethacin: the risk factors and mechanisms of its development]. Ter Arkh 67: 36-39
51. Carvallo A, Rakowski TA, Argy WP jr, Schreiner GE (1978) Acute renal failure following drip infusion pyelography. Am J Med 65: 38-45
52. Erley C (2006) Concomitant drugs with exposure to contrast media. Kidney Int [suppl]: S20-S24
53. Cirit M, Toprak O, Yesil M et al. (2006) Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract 104: c20-c27
54. Louis BM, Hoch BS, Hernandez C et al. (1996) Protection from the nephrotoxicity of contrast dye. Ren Fail 18: 639-646
55. Dangas G, Iakovou I, Nikolsky E et al. (2005) Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 95: 13-19
56. Bailey CJ, Turner RC (1996) Metformin. N Engl J Med 334: 574-579
57. Deray G (2006) Dialysis and iodinated contrast media. Kidney Int [suppl]: S25-S29
58. Cruz DN, Perazella MA, Bellomo R et al. (2006) Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Kidney Dis 48: 361-371
59. Marenzi G, Marana I, Lauri G et al. (2003) The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 349: 1333-1340
60. Marenzi G, Lauri G, Campodonico J et al. (2006) Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med 119: 155-162
61. Green LV (2002) How many hospital beds? Inquiry 39: 400-412
62. Solomon R, Briguori C, Bettmann M (2006) Selection of contrast media. Kidney Int [suppl]: S39-S45
63. Lufft V, Hoogestraat-Lufft L, Fels LM et al. (2002) Contrast media nephropathy: intravenous CT angiography versus intraarterial digital subtraction angiography in renal artery stenosis: a prospective randomized trial. Am J Kidney Dis 40: 236-242
64. Solomon R, Dumouchel W (2006) Contrast media and nephropathy: findings from systematic analysis and Food and Drug Administration reports of adverse effects. Invest Radiol 41: 651-660
65. Erley CM, Bader BD, Berger ED et al. (2004) Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients. Nephrol Dial Transplant 19: 2526-2531
66. Ergun I, Keven K, Uruc I et al. (2005) The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol Dial Transplant: gfi304
67. Thomsen HS, Morcos SK (2006) ESUR guidelines on contrast media. Abdom Imaging 31: 131-140
68. Thomsen HS (2005) How to avoid CIN: guidelines from the European Society of Urogenital Radiology. Nephrol Dial Transplant 20 [suppl 1]: i18-i22